Cargando…
Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients
BACKGROUND: Whereas accumulating studies on patients with coronavirus disease 2019 (COVID‐19) report high incidences of thrombotic complications, large studies on clinically relevant thrombosis in patients with other respiratory tract infections are lacking. How this high risk in COVID‐19 patients c...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014477/ https://www.ncbi.nlm.nih.gov/pubmed/33821230 http://dx.doi.org/10.1002/rth2.12496 |
_version_ | 1783673560476155904 |
---|---|
author | Stals, Milou A. M. Grootenboers, Marco J. J. H. van Guldener, Coen Kaptein, Fleur H. J. Braken, Sander J. E. Chen, Qingui Chu, Gordon van Driel, Erik M. Iglesias del Sol, Antonio de Jonge, Evert Kant, K. Merijn Pals, Fleur Toorop, Myrthe M. A. Cannegieter, Suzanne C. Klok, Frederikus A. Huisman, Menno V. |
author_facet | Stals, Milou A. M. Grootenboers, Marco J. J. H. van Guldener, Coen Kaptein, Fleur H. J. Braken, Sander J. E. Chen, Qingui Chu, Gordon van Driel, Erik M. Iglesias del Sol, Antonio de Jonge, Evert Kant, K. Merijn Pals, Fleur Toorop, Myrthe M. A. Cannegieter, Suzanne C. Klok, Frederikus A. Huisman, Menno V. |
author_sort | Stals, Milou A. M. |
collection | PubMed |
description | BACKGROUND: Whereas accumulating studies on patients with coronavirus disease 2019 (COVID‐19) report high incidences of thrombotic complications, large studies on clinically relevant thrombosis in patients with other respiratory tract infections are lacking. How this high risk in COVID‐19 patients compares to those observed in hospitalized patients with other viral pneumonias such as influenza is unknown. OBJECTIVES: To assess the incidence of venous and arterial thrombotic complications in hospitalized patients with influenza as opposed to that observed in hospitalized patients with COVID‐19. METHODS: This was a retrospective cohort study; we used data from Statistics Netherlands (study period: 2018) on thrombotic complications in hospitalized patients with influenza. In parallel, we assessed the cumulative incidence of thrombotic complications—adjusted for competing risk of death—in patients with COVID‐19 in three Dutch hospitals (February 24 to April 26, 2020). RESULTS: Of the 13 217 hospitalized patients with influenza, 437 (3.3%) were diagnosed with thrombotic complications, versus 66 (11%) of the 579 hospitalized patients with COVID‐19. The 30‐day cumulative incidence of any thrombotic complication in influenza was 11% (95% confidence interval [CI], 9.4–12) versus 25% (95% CI, 18–32) in COVID‐19. For venous thrombotic (VTC) complications and arterial thrombotic complications alone, these numbers were, respectively, 3.6% (95% CI, 2.7–4.6) and 7.5% (95% CI, 6.3–8.8) in influenza versus 23% (95% CI, 16–29) and 4.4% (95% CI, 1.9–8.8) in COVID‐19. CONCLUSIONS: The incidence of thrombotic complications in hospitalized patients with influenza was lower than in hospitalized patients with COVID‐19. This difference was mainly driven by a high risk of VTC complications in the patients with COVID‐19 admitted to the Intensive Care Unit. Remarkably, patients with influenza were more often diagnosed with arterial thrombotic complications. [Image: see text] |
format | Online Article Text |
id | pubmed-8014477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80144772021-04-01 Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients Stals, Milou A. M. Grootenboers, Marco J. J. H. van Guldener, Coen Kaptein, Fleur H. J. Braken, Sander J. E. Chen, Qingui Chu, Gordon van Driel, Erik M. Iglesias del Sol, Antonio de Jonge, Evert Kant, K. Merijn Pals, Fleur Toorop, Myrthe M. A. Cannegieter, Suzanne C. Klok, Frederikus A. Huisman, Menno V. Res Pract Thromb Haemost Original Articles ‐ Thrombosis BACKGROUND: Whereas accumulating studies on patients with coronavirus disease 2019 (COVID‐19) report high incidences of thrombotic complications, large studies on clinically relevant thrombosis in patients with other respiratory tract infections are lacking. How this high risk in COVID‐19 patients compares to those observed in hospitalized patients with other viral pneumonias such as influenza is unknown. OBJECTIVES: To assess the incidence of venous and arterial thrombotic complications in hospitalized patients with influenza as opposed to that observed in hospitalized patients with COVID‐19. METHODS: This was a retrospective cohort study; we used data from Statistics Netherlands (study period: 2018) on thrombotic complications in hospitalized patients with influenza. In parallel, we assessed the cumulative incidence of thrombotic complications—adjusted for competing risk of death—in patients with COVID‐19 in three Dutch hospitals (February 24 to April 26, 2020). RESULTS: Of the 13 217 hospitalized patients with influenza, 437 (3.3%) were diagnosed with thrombotic complications, versus 66 (11%) of the 579 hospitalized patients with COVID‐19. The 30‐day cumulative incidence of any thrombotic complication in influenza was 11% (95% confidence interval [CI], 9.4–12) versus 25% (95% CI, 18–32) in COVID‐19. For venous thrombotic (VTC) complications and arterial thrombotic complications alone, these numbers were, respectively, 3.6% (95% CI, 2.7–4.6) and 7.5% (95% CI, 6.3–8.8) in influenza versus 23% (95% CI, 16–29) and 4.4% (95% CI, 1.9–8.8) in COVID‐19. CONCLUSIONS: The incidence of thrombotic complications in hospitalized patients with influenza was lower than in hospitalized patients with COVID‐19. This difference was mainly driven by a high risk of VTC complications in the patients with COVID‐19 admitted to the Intensive Care Unit. Remarkably, patients with influenza were more often diagnosed with arterial thrombotic complications. [Image: see text] John Wiley and Sons Inc. 2021-04-08 /pmc/articles/PMC8014477/ /pubmed/33821230 http://dx.doi.org/10.1002/rth2.12496 Text en © 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles ‐ Thrombosis Stals, Milou A. M. Grootenboers, Marco J. J. H. van Guldener, Coen Kaptein, Fleur H. J. Braken, Sander J. E. Chen, Qingui Chu, Gordon van Driel, Erik M. Iglesias del Sol, Antonio de Jonge, Evert Kant, K. Merijn Pals, Fleur Toorop, Myrthe M. A. Cannegieter, Suzanne C. Klok, Frederikus A. Huisman, Menno V. Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients |
title | Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients |
title_full | Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients |
title_fullStr | Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients |
title_full_unstemmed | Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients |
title_short | Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients |
title_sort | risk of thrombotic complications in influenza versus covid‐19 hospitalized patients |
topic | Original Articles ‐ Thrombosis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014477/ https://www.ncbi.nlm.nih.gov/pubmed/33821230 http://dx.doi.org/10.1002/rth2.12496 |
work_keys_str_mv | AT stalsmilouam riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT grootenboersmarcojjh riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT vanguldenercoen riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT kapteinfleurhj riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT brakensanderje riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT chenqingui riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT chugordon riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT vandrielerikm riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT iglesiasdelsolantonio riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT dejongeevert riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT kantkmerijn riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT palsfleur riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT tooropmyrthema riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT cannegietersuzannec riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT klokfrederikusa riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT huismanmennov riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients AT riskofthromboticcomplicationsininfluenzaversuscovid19hospitalizedpatients |